The present study was designed to evaluate the protective effects of Reduning injection against Enterovirus 71(EV71) in Vero cells and in mice. The Vero cells were infected with 100 and 50 TCID50(50% tissue culture in...The present study was designed to evaluate the protective effects of Reduning injection against Enterovirus 71(EV71) in Vero cells and in mice. The Vero cells were infected with 100 and 50 TCID50(50% tissue culture infective dose) of EV71, respectively. The inhibition of Reduning injection on cytopathic effect(CPE) was detected. Meanwhile, a mouse model produced by intraperitoneal EV71-infection(106 TCID50), was used to investigate the protective effects of Reduning injection. The total survival rate, living time, daily survival rate, weight ratio, and score for symptoms were examined. The viral loads in Vero cells and muscle tissues were detected using real-time PCR. Finally, the content of cytokines was analyzed by ELISA. In the Vero cells, 2.5 mg crude drug·m L-1 of Reduning injection inhibited CPE induced by EV71 infection. In the mice, 1.3 g crude drug·kg-1 of Reduning injection rescued death triggered by infection, in comparison with model group. Moreover, the survival rate, weight ratio, and clinical scores were also improved. The viral RNA copies in the Vero cells and the mice muscle tissues were reduced. Besides, the steep EV71-induced accumulations of TNF-α and MCP-1 were decreased by Reduning injection. In conclusion, Reduning injection showed promising protective effects against EV71 in Vero cells and in mice.展开更多
文摘目的 评价不同细胞基质制备的肠道病毒71型（EV71）灭活疫苗上市后常规免疫安全性。 方法 EV71灭活疫苗疑似预防接种异常反应（AEFI）数据来源于中国免疫规划信息管理系统，为2017年接种EV71 灭活疫苗后江苏省报告的监测数据；受种儿童人口学信息和接种剂次数来源于江苏省预防接种信息管理系统。 结果 2017年江苏省共接种EV71灭活疫苗316 889剂，报告AEFI 208例，报告发生率为65.64/10万剂（95% CI ：56.72/10万剂～74.56/10万剂），其中一般反应55.54/10万剂（95% CI ：47.34/10万剂～63.74/10万剂），异常反应 7.89/10万剂（95% CI ：4.80/10万剂～10.98/10万剂）；不同细胞基质的疫苗AEFI发生率（χ 2 =35.61， P ＜0.01）和一般反应发生率（χ 2 =34.09， P ＜0.01）差异有统计学意义，异常反应发生率差异无统计学意义（χ 2 =1.88， P =0.17），均未见严重异常反应，208例AEFI均未住院且均痊愈。EV71灭活疫苗（Vero细胞）首剂接种一般反应发生率高于第二剂（χ 2 =6.94， P ＜0.01），不同季度接种EV71灭活疫苗（人二倍体细胞）一般反应发生率差异有统计学意义（χ 2 =18.86， P ＜0.01）。 结论 不同细胞基质的EV71灭活疫苗在常规免疫接种中AEFI发生率均不高，有良好的安全性；一般反应以发热为主，异常反应以过敏性-荨麻疹、过敏性皮疹和过敏性斑丘疹等过敏性反应为主。
基金supported by National Major New Drugs Innovation and Development Project from Ministry of Science and Technology of China(2013ZX09402203)
文摘The present study was designed to evaluate the protective effects of Reduning injection against Enterovirus 71(EV71) in Vero cells and in mice. The Vero cells were infected with 100 and 50 TCID50(50% tissue culture infective dose) of EV71, respectively. The inhibition of Reduning injection on cytopathic effect(CPE) was detected. Meanwhile, a mouse model produced by intraperitoneal EV71-infection(106 TCID50), was used to investigate the protective effects of Reduning injection. The total survival rate, living time, daily survival rate, weight ratio, and score for symptoms were examined. The viral loads in Vero cells and muscle tissues were detected using real-time PCR. Finally, the content of cytokines was analyzed by ELISA. In the Vero cells, 2.5 mg crude drug·m L-1 of Reduning injection inhibited CPE induced by EV71 infection. In the mice, 1.3 g crude drug·kg-1 of Reduning injection rescued death triggered by infection, in comparison with model group. Moreover, the survival rate, weight ratio, and clinical scores were also improved. The viral RNA copies in the Vero cells and the mice muscle tissues were reduced. Besides, the steep EV71-induced accumulations of TNF-α and MCP-1 were decreased by Reduning injection. In conclusion, Reduning injection showed promising protective effects against EV71 in Vero cells and in mice.
